Greece
Key Insights
- 1
No psychedelic medicine is approved in Greece; ketamine and esketamine are available only through authorised medical use, while psilocybin remains trial-only.
- 2
Greece has 5 recorded trials, 2 active, across 3 organisations; ketamine, esketamine and psilocybin dominate, with placebo in the active mix.
- 3
Greece’s modern milestone is regulatory, not commercial: there is no national psychedelic approval, so research is the country’s main legal pathway.
- 4
Momentum sits with academic psychiatry centres, especially the National and Kapodistrian University of Athens, which anchors the country’s small but active trial base.
Reimbursed Care Access
Greece maintains a restrictive controlled‑substances regime under Law 4139/2013; licensed pharmaceutical psychedelics that have EU marketing authorisations (currently esketamine/Spravato) are available under tight clinical controls, but routine public reimbursement and broad medical access for classic psychedelics (psilocybin, MDMA, DMT, etc.) do not exist outside approved clinical research. Off‑label clinical use of ketamine for anesthesia and some private off‑label psychiatric uses occurs, but most other compounds remain scheduled with no authorized medical use outside clinical trials or special authorised programmes.
Quick Indicators
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Greece.